In December, we highlight three articles. Tsao et al provide an overview of advances in lung cancer pathology over the last forty years and highlight the role of IASLC in these advances - Forty Years of the International Association for Study of Lung Cancer (IASLC) Pathology Committee. Asiedu and colleagues discuss genetic aberrations in carcinoid cell lines that were generated and sequenced by their group - Generation and sequencing of pulmonary carcinoid tumor cell lines, and finally Litvak et al discuss the clinical characteristics as well as clinical outcomes in patients with thymic carcinoma - Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging. Dr Nicolas Girard has an insightful editorial accompanying the Litvak article as well as a second article on a phase II study of amrubicin in thymic carcinoma.
Alex A. Adjei, MD, PhD, Editor-in-Chief